OTCMKTS:CYTR LadRx (CYTR) Stock Price, News & Analysis → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free CYTR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.0952-Week Range N/AVolume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LadRx alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About LadRx Stock (OTCMKTS:CYTR)LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.Read More Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW CYTR Stock News HeadlinesAugust 11, 2023 | finance.yahoo.comLadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo FinanceNovember 27, 2022 | finance.yahoo.comLadRx Corporation Issues Corporate Update for 3Q22April 25, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...October 5, 2022 | businesswire.comLadRx Corporation Announces OTCQB Ticker Change to LADX - Business WireSeptember 23, 2022 | marketscreener.comCYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSeptember 23, 2022 | businesswire.comCytRx Corporation Relaunches as LadRx Corporation - Business WireSeptember 7, 2022 | businesswire.comEuropean Patent Office Awards CytRx Key Patent - Business WireAugust 25, 2022 | marketscreener.comADIAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comApril 25, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...August 21, 2022 | reuters.comCYTR.PK - CytRx Corporation | Stock Price & Latest News | ReutersAugust 9, 2022 | businesswire.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Business WireAugust 9, 2022 | finance.yahoo.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsJuly 27, 2022 | marketscreener.comCYTRX CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.comMay 20, 2022 | stockhouse.com2022-05-19 | OTCQB:CYTR | Press Release | CytRx Corporation - StockhouseMay 20, 2022 | businesswire.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Business WireMay 20, 2022 | marketscreener.comCYTRX CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comMay 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Yahoo FinanceMay 19, 2022 | marketscreener.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Marketscreener.comMay 17, 2022 | finance.yahoo.comCytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.May 16, 2022 | streetinsider.comArcellx (ACLX) Appoints Olivia Ware to its Board - StreetInsider.comApril 20, 2022 | businesswire.comCytRx Partners with Oncology Development Expert to Advance LADR Platform - Business WireApril 20, 2022 | finance.yahoo.comCytRx Partners with Oncology Development Expert to Advance LADR PlatformApril 13, 2022 | prnewswire.comGene Therapies & Associated Vectors 2022: Intellectual Property Landscape, Patent Valuation Analysis, Granted Patents and Claims Analysis - PR NewswireMarch 25, 2022 | streetinsider.comForm 424B3 CYTRX CORP - StreetInsider.comMarch 23, 2022 | benzinga.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Benzinga - BenzingaMarch 23, 2022 | marketscreener.comCYTRX CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 21, 2022 | finance.yahoo.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Yahoo FinanceSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2019Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CYTR CUSIPN/A CIK799698 Webwww.cytrx.com Phone(310) 826-5648Fax310-826-6139Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.61% Return on Assets-45.39% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free Float33,834,000Market Cap$4.14 million OptionableNot Optionable Beta1.96 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. John Y. Caloz (Age 70)CFO, Treasurer & Sr. VP Comp: $500kDr. Stephen Snowdy Ph.D. (Age 52)Chief Exec. Officer Molly Carey PoarchGlobal & U.S. Head of Corp. CommunicationsMs. Molly Painter (Age 46)Pres of USA and Head of Launch & Commercial Operations Terri StevensChief Bus. OfficerMs. Cristina NewmanCorp. Sec.Dr. Felix Kratz Ph.D. (Age 59)Sr. VP, Drug Devel. More ExecutivesKey CompetitorsTRACON PharmaceuticalsNASDAQ:TCONFinch Therapeutics GroupNASDAQ:FNCHPharmaCyte BiotechOTCMKTS:PMCBDKiromic BioPharmaNASDAQ:KRBPPalisade BioNASDAQ:PALIView All Competitors CYTR Stock Analysis - Frequently Asked Questions How were LadRx's earnings last quarter? LadRx Co. (OTCMKTS:CYTR) posted its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. When did LadRx's stock split? Shares of LadRx reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of LadRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other LadRx investors own include Anavex Life Sciences (AVXL), Biopharmx (BPMX), Rexahn Pharmaceuticals (REXN), Idera Pharmaceuticals (IDRA), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Marinus Pharmaceuticals (MRNS) and How do I buy shares of LadRx? Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYTR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
